ANVS

Annovis is a single-asset, pre-revenue clinical-stage biotech whose entire value rests on buntanetap, an oral small molecule in a pivotal 760-patient Phase 3 early-Alzheimer's trial (NCT06709014, initiated Feb 2025) plus a PD open-label extension and a still-unfunded PDD study. Five straight years of zero revenue ($0.00 in FY2021–FY2025) and accumulated deficit of -$164M tell you this is a science wager: there are no fundamentals to value, only a probability-weighted readout. The FY2025 net loss was -$28.9M with operating cash flow of -$25.6M, and R&D rose 26.1% to $25.2M as the Phase 3 ramped.

The decisive problem is the funding cliff. Cash and equivalents were $19.5M at FY2025 against a -$25.6M annual operating burn — under a year of runway against a multi-year Phase 3 whose symptomatic 6-month portion is only the first of two readouts (18-month disease-modification follow-on after that). Management itself states the PDD program 'will initiate the study contingent on additional funding,' and shares outstanding already jumped 45.5% to 28.4M in one year. The 85% cash increase and 81% equity rise came from issuing stock, not operations — meaning shareholders should expect continued, heavy dilution at a depressed ~$1.86 price simply to keep the lights on and fund the trial.